Categories
Basic Immunology Multiple Sclerosis

KIR4.1 antibodies: A revolution in multiple sclerosis

This week we had the opportunity to read a paper in the New England Journal of Medicine, describing, in my opinion, a breakthrough finding in MS. It’s published by Srivastava and coworkers, from the University of Munich. It describes the presence of antibodies against the KIR4.1 potassium channel in almost 50% of MS patients. Maybe […]

Categories
Multiple Sclerosis Therapy

Pills for multiple sclerosis

It’s been a while since i wrote last post, but NeuroImmunology has been busy with several other projects. It’s been a while too since i decided to write a monographic post about the different oral treatments that are already available or are about to arrive but i postponed it until i had enough time to […]

Categories
Basic Immunology Multiple Sclerosis

Does multiple sclerosis start from the gut?

MS scientific literature is fascinating. Few neurological (and non-neurological) diseases can compete in number of papers, impact factor and mainstream media attention. However many research projects use classical animal models (experimental allergic encephalmyelitis, EAE) and those animal models have been an enormous source of erroneous extrapolations to MS pathogenesis. Many times the EAE model has […]

Categories
Multiple Sclerosis

Interferons, get out!

Today New England Journal of Medicine makes public the results of a large clinical trial with more than a thousand patients comparing results of teriflunomide against placebo in MS. Results are not spectacular, but not bad. It decreased a 30% the annualized relapse rate and reduced the rate of disability progression slightly. The best point […]

Categories
Multiple Sclerosis Therapy

Chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis: a reasonable approach.

Chronic cerebrospinal venous insufficiency is a novel hypothesis, proposed for the first time by Dr Paolo Zamboni, to try to explain the elusive cause of multiple sclerosis (MS). Briefly, this hypothesis proposes that the autoimmune attack against oligodendrocytes and the demyelination process, hallmarks of MS pathology, are caused by an excessive deposition of iron around […]

Categories
Multiple Sclerosis Therapy

Progressive multifocal leukoencephalopahy and Rituximab

In a previous post we discussed the shameful oblivion in which Rituximab has been left apart because of its patent expiry date. Just this week a new paper on Archives of Neurology deepens our disappointment. Besides the great efficacy of Rituximab, maybe comparable to that of Natalizumab¬†(or even better as seen in their phase II […]

Categories
Multiple Sclerosis Therapy

Fingolimod, two years view

The last issue of the Lancet Neurology journal, has published the extension phase study of the TRANSFORMS trial. Briefly, the TRANSFORMS trial was a randomized controlled trial comparing i.m. interferon beta 1a versus two different doses of fingolimod (0.5mg and 1.25mg). Its results were published on New England Journal of Medicine on February 2010, together […]

Categories
Multiple Sclerosis

The shameful story of Rituximab in Multiple Sclerosis

Two weeks ago a few collegues from Spain and ¬†I attended the 3rd Preceptorship Program in MS at Steven Hauser’s department in UCSF. The scientific program and the overall quality of the course were outstanding. We had the opportunity to hear and ask those that have been ahead of MS research in the last years […]

Categories
Multiple Sclerosis

Fingolimod approved!

First, the good news, a week ago the EMEA informed positively for Gilenya (Fingolimod) approval. This will expand the spectrum of therapeutic options for patients with multiple sclerosis and will fulfill the long desired availability of oral drugs for that chronic disease. The bad news are that only selected patients will have access to this […]

Categories
Disimmune neuropathies Inflammatory myopathies Multiple Sclerosis Myasthenia Gravis Others Paraneoplastic disorders

Plasmapheresis guidelines for NeuroImmune disorders

AAN evidence based reviews don’t add anything new to what we probably know (or should know) or suspect about a treatment or intervention, but it’s always useful to have all data summarized to avoid the whole process of revision by oneself. In the last issue of Neurology journal we’ll find an evidence-based review about the […]